个人简介：
刘滨磊，博士生导师、湖北工业大学特聘教授、湖北省相关人才项目入选者，“3551光谷人才计划”入选者。研究方向：肿瘤免疫治疗、生物制药、溶瘤病毒。
刘教授致力于肿瘤免疫及溶瘤病毒研究，在溶瘤病毒领域的研发工作达到国际领先水平。其在英国负责研发的抗癌新药T-VEC，是第一个临床III期试验证明有效的溶瘤病毒。已获美国FDA及欧盟EMEA批准上市销售。2011年初，T-VEC被Amgen公司以10亿美金收购。归国后，刘滨磊教授带领国内研究团队研发出具有抗癌疗效更强的肿瘤免疫治疗药物“溶瘤性II型单纯疱疹病毒”。该项目目前已完成临床前研究，获得国家药品监督管理局药物临床试验批件（批件号：2018L02743），已完成I/II期临床研究，启动III期临床试验。已获得的立项资助有重大新药创制、973、863、十二五支撑项目、自然科学基金等。迄今为止，已在国内外杂志发表40余篇科研论文。
招生信息
1.招生学科：生物工程、微生物与生化药、生物制药、生物化工、生物医药
2.研究方向：溶瘤病毒、肿瘤生物治疗
3.招生年度：2023
科研项目
1.1、2018-2020，国家重大新药创制项目，《基因治疗溶瘤病毒1类新药的临床前和临床研究》，批准号：2018ZX09733002，子课题主持
1.2、2015-2018,国家自然科学基金面上项目,《择瘤繁殖并表达绿色荧光蛋白的单纯疱疹病毒检测循环肿瘤细胞》,批准号：81472013,72万,项目负责人
1.3、2014-2017,“十二五”国家科技支撑计划,《恶性肿瘤靶基因捕获技术等转化医学平台》,批准号：2014BAI09B04,262万,子课题负责人
1.4、2012-2015, 973,项目《恶性肿瘤免疫负调控网络》,批准号：2012CB917104，140万，子课题负责人
1.5、2012-2015, 863,项目《疫苗研发关键技术及产品研发》,批准号：2012AA02A407, 37,子课题负责人
1.6、2013.1-2014.12,国自然海外及港澳合作项目,《溶瘤病毒模拟急性感染以改善肿瘤微环境增加慢病毒肿瘤疫苗的抗瘤效果》,批准号：81228015,20,项目负责人
1.7、2012.1-2015.12,国家自然科学基金面上项目,《表达人端粒酶趋化抗原的溶瘤性单纯疱疹病毒的抗肿瘤机制研究》,批准号：81172160,60,项目负责人
1.8、2012.7-2014.6,国家中小企业创新基金,《抗肿瘤新型治疗性疫苗--重组II型单纯疱疹病毒制剂的临床前产业化研究》,立项号：12C26214204582,70,项目负责人
1.9、2013.1-2014.12,武汉市科技攻关项目,《抗肿瘤新药溶瘤II型单纯疱疹病毒制剂的临床前产业化研究》,任务书号：2013060602010228,20,项目负责人
2.0、2010.11-2013.9,天津市科委科技支撑重点项目,《溶瘤性重组Ⅱ型单纯疱疹病毒临床制剂的研制》,合同编号10ZCKFSY08000,50,项目负责人
2.1、2010.7-2013.7,武汉东湖新技术开发区“3551人才”项目,100,项目负责人
2.2、2011.1-2011.12,国家自然科学基金主任专项基金,《表达人端粒酶趋化抗原的溶瘤性单纯疱疹病毒的抗肿瘤机制研究》批准号：81041034,10,项目负责人
2.3、2009.10-2012.10,“重大新药创制”科技重大专项项目项目编号：2009ZX09103-725,132.17,科研骨干
成果获奖
代表性文章：
1.Wang, Y., Jin, J., Li, Y., Zhou, Q., Yao, R., Wu, Z., Hu, H., Fang, Z., Dong, S., Cai, Q., Hu, S., & Liu, B. (2022). NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. Translational research : the journal of laboratory and clinical medicine, 240, 64–86. https://doi.org/10.1016/j.trsl.2021.10.006
2. Hu, H, Zhang, S., Cai, L., Duan, H., Li, Y., & Yang, J., et al. (2022). A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, pd1v, and IL-7×CCL19 results in enhanced antitumor efficacy. Virology Journal, 19(1), 1-12.
3.Wen Zhang, Xiao Hu, Jing Liang, Yujie Zhu, Beibei Zeng, Lin Feng, Changyun Zhao, Shangmei Liu, Binlei Liu*, and Kaitai Zhang. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity. Molecular Therapy Oncolytics, 2020, vol. 16
4.Han Hu, Ziyi Zhang, Runyang Wang, Yang Wang, Jing Jin, Linkang Cai, Junhan Yang, Haixiao Duan, Zhen Wu, Zhizheng Fang, Binlei Liu*. BGC823 Cell Line with the Stable Expression of iRFP720 Retains Its Primary Properties with Promising Fluorescence Imaging Ability. DNA and Cell Biology, 2020, DOI: 10.1089/dna.2019.5057
5.Linkang Cai, Han Hu, Haixiao Duan, Yuying Li, Zongxing Zou, Kailun Luo, Ziyi Zhang, Junhan Yang, Jing Jin1, Ying Chen, Zonghuang Ke, Zongyao Fang, Qiong Liu, Xiaoqian Hong, Sheng Hu, Binlei Liu*. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology. Journal of Medical Virology, 2020, DOI: 10.1002/jmv.25691
6.Yujie Zhu, Xiao Hu, Lin Feng, Zhenrong Yang, Lulin Zhou, Xinchun Duan, Shujun Cheng, Wen Zhang, Binlei Liu*, Kaitai Zhang. Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1. Molecular Therapy: Oncolytics, 2019, 15: 201-213. https://doi.org/10.1016/j.omto.2019.10.003.
7.Wen Zhang*, Feifei Wang*, Xiao Hu, Jing Liang, Binlei Liu, Qi Guan, Shangmei Liu. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity. Oncology Letters, 2019, 17: 815-822.
8.Preclinical safety evaluation of oncolytic herpes simplex virus type 2. Wang Yang, Zhou Xiaobing, Wu Zhen, Hu Han, Jin Jing, Hu Yanping, Dong Yuting, Zou Jianwen, Mao Zeyong, Shi Xiaotai, Huo Yan, Lyu Jianjun, Fang Zhizheng, Zhang Wen, Zhu Yujie, Li Bo, Liu Binlei*. Human Gene therapy, 2018, DOI: 10.1089/hum.2018.170.
9.Stability and anti-tumor effect of oncolytic herpes simplex virus type 2. Wang Yang, Jing Jin, Zhen Wu, Sheng Hu, Han Hu, Zhifeng Ning, Yanfei Li, Yuting Dong, JianwenZou, Zeyong Mao, Xiaotai Shi, Huajun Zheng, Shuang Dong, Fuxing Liu, Zhizheng Fang, Jiliang Wu and Binlei Liu*. Oncotarget, 2018, 9:24672-24683.
10.Yang HB, Peng T, Li J, Zhang W, Zhang P, Peng S, Du T, Li YF, Yan Q, Liu BL*; Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models. Gene Therapy 2016, 23(5):450.
11.Zhang W, Bao L, Yang SX, Qian ZY, Dong M, Yin LY, Zhao Q, Ge KL, Deng ZL, Zhang J, Qi F, An ZX , Yu Y, Wang QB, Wu RH, Fan F, Zhang LF, Chen XP, Na YJ , Feng L, Li J, Zhang Y, Dong Y, Zhang SR, Zhang YH , Zhang XQ , Wang J, Yi X, Zou L, Xin HW, Ditzel HJ, Gao H, Zhang KT, Liu BL*, Cheng SJ; Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells. Oncotarget 2016, 7(26):39768.
12.Zhang W, Ge K, Zhao Q, Li J, Zhang Y, Dong Y, Zhang S, Liu B *; A novel oncolytic herpes simplex virus type-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4. Oncotarget, 2015，6：20345-20355.
13.Guilan Shi, Chunxia Zhou, Dongmei Wang, Wenbo Ma, Binlei Liu*, Shuren Zhang; Antitumor enhancement by adoptive transfer of tumor antigen primed, inactivated MHC-haploidentical lymphocyte. Cancer Letter 2014, 343:42-50.
14.Zhuang X, Wen Zhang, Chen Y, Han X, Li J, Zhang Y, Zhang Y, Zhang S, Liu B*; Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer 2012, 12:549.
15.Tang Y-S, Wang D, Zhou C, Ma W, Zhang Y-Q, Liu B* and Zhang S; Bacterial magnetic particles as a novel and efficient gene vaccine delivery system. Gene Therapy 2012 Dec;19(12):1187-1195. IF4.538
16.Zhao L, Liu BL*, Ren J, Feng J, Pang Z, Gao J, Zhang H, Tan WJ, Tian HW, Ruan L; Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. Virology Journal 2011, 8:302 . IF2.546
17.Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS; Development of a second-generation oncolytic Herpes simplex virus expressing TNF for cancer therapy. The Journal of Gene Medicine 2007 Jan; 9(2):99-106
18.Simpson GR, Han ZQ, Liu BL, Wang YB, Campbell G and Coffin RS; Combination of a fusogenic glycoprotein prodrug activation, and oncolytic herpes simplex virus for enhanced local tumour control. Cancer Res. 2006 May 1;66 (9):4835-4842 16651439
19.Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS; ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy. 2003 Feb;10(4):292-303.
20.Deng Y, Batten CA, Liu BL, Lambden PR, Elschner M, Gunther H, Otto P, Schnurch P, Eichhorn W, Herbst W, Clarke IN.; Studies of epidemiology and seroprevalence of bovine noroviruses in Germany. J Clin Microbiol. 2003 Jun;41(6):2300-5
21.Everson JS, Garner SA, Fane B, Liu BL, Lambden PR, Clarke IN.; Biological properties and cell tropism of Chp2, a bacteriophage of the obligate intracellular bacterium Chlamydophila abortus. J Bacteriol. 2002 May; 184(10):2748-54
22.Liu, B-L., Everson, J. S., Giannikopoulou, P., Vretou, E., Lambden, P.R., and Clarke, I.N.; Molecular characterization of a bacteriophage from Chlamydia psittaci. Journal of Virology. 74, 3464-3469 (2000).
23.Christodoulides, M., Everson, J. S., Liu, B-L., Lambden, P.R., Thomas, E., Watt, P.J., and Heckels, J.E.; Interaction of primary human endometrial cells with Nessaria gonorrhoea expressing green fluorescent protein. Molecular Microbiology. 35(1), 32-43 (2000).
24.Liu, B-L., Lambden, P.R.,. Gunther, H., Otto, P., Elschner, M and Clarke, I.N.; Molecular characterisation of a bovine enteric calicivirus: relationship to the Norwalk-like viruses. Journal of Virology 73, 819-825 (1999).
25.Liu, B-L., Viljoen G.J., Clarke, I.N. and Lambden, P.R.; Identification of further proteolytic cleavage sites in the Southampton calicivirus polyprotein by expression of the viral protease in E.coli. Journal of General virology 80, 291-296 (1999).
26.Pelosi, E, Lambden, P.R., Caul, E.O., Liu, B-L., Dingle, K., Deng Y. and Clarke, I.N.; The seroepidemiology of genogroup 1 and genogroup 2 Norwalk-like viruses in Italy. Journal of Medical Virology 58:1, 93-9 (1999).
27.Noel, J.S., Liu, B.L., Humphrey, E.M., Rodrriguez, E.M., Lambden, P.R., Clarke, I.N., Dwyer, D.M., Ando. T. Monroe, S.S. and Glass, R.I.; Human calicivirus associated with an outbreak of gastroenteritis in adults: A novel genetic variant in the Sapporo virus clade. J. Med. Virol. 52, 173 - 178 (1997).
28.Liu, B-L., Clarke, I.N., Caul, E.O. and Lambden, P.R.; The genomic 5’ terminus of Manchester calicivirus. Virus Genes 15:1, 25-28 (1997)
29.Liu, B-L., Clarke, I.N., and Lambden, P.R.; Polyprotein processing in Southampton Virus: Identification of 3C protease cleavage sites by in vitro mutagenesis Journal of Virology. 70, 2605-2610 (1996).
30.Liu, B-L., Clarke, I.N., Caul, E.O. and Lambden, P.R.; Human enteric caliciviruses have a unique genome structure and are distinct from the Norwalk-like viruses. Archives of Virology 140, 1345-1356 (1995).
31. Lambden, P.R., Liu, B-L., and Clarke, I.N.; A conserved sequence motif at the 5´ terminus of the Southampton virus genome is characteristic of the Caliciviridae. Virus Genes 10:2, 149-152 (1995).
第一发明人授权的专利：
重组II型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及其应用，专利申请号为201010116275.3，已授权。
重组II型单纯疱疹病毒、其制备方法及应用和肿瘤诊断试剂盒。专利申请号201010162070.9，已授权。
重组单纯疱疹病毒、其制备方法及应用。专利申请号201210337627.7，已进入实审并申请了国际专利。
专著发表：
《预防肿瘤学》第四篇第二十五章：免疫与癌。由赵平、王陇德及黎钧耀主编。
